In our work, using a NAFLD model that is a consequence of metabolic syndrome and obesity, we showed that eNOS−/− mice fed a HFD and treated with Met had a decrease in intraperitoneal fat accumulation and liver steatosis, as well as a reduction in their progression to NASH. This evidence concerns the gene NOS3 and metabolic dysfunction-associated steatohepatitis.